Why BioLife Solutions, Inc.’s (BLFS) Stock Is Up 9.03%
As of Tuesday, July 28, BioLife Solutions, Inc.’s BLFS share price has surged by 9.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: BioLife Solutions, Inc. (BLFS)
BioLife Solutions, Inc. BLFS
$35.50
-0.42
-1.17%
September 3, 2026 10:45:35 AM
EST
Volume: 61,599
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Commentary & Analysis
Why BioLife Solutions, Inc.’s (BLFS) Stock Is Up 10.17%
As of Tuesday, July 28, BioLife Solutions, Inc.’s BLFS share price has surged by 10.17%, which has investors questioning if this is right time to sell.Jenna Brashear
Why BioLife Solutions, Inc.’s (BLFS) Stock Is Up 5.52%
As of Wednesday, July 22, BioLife Solutions, Inc.’s BLFS share price has surged by 5.52%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why BioLife Solutions, Inc.’s (BLFS) Stock Is Up 5.45%
As of Friday, June 26, BioLife Solutions, Inc.’s BLFS share price has surged by 5.45%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why BioLife Solutions, Inc.’s (BLFS) Stock Is Up 6.16%
As of Thursday, June 25, BioLife Solutions, Inc.’s BLFS share price has surged by 6.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | BLFS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,756.7 | $3,681.2 | 52% |
|
| Shares Out (Mil) | 49.3 | 98.2 | 47% |
|
| Institutional Ownership | 97.0% | 89.6% | 72% |
|
| Float (Mil) | 42.8 | 70.7 | 44% |
|
| Beta | 1.90 | 1.19 | 91% |
|
| Avg Daily Volume (000s) | 961 | 652 | 71% |
|
| Price Change (52-week) |
41.8% | 87.5% | 77% |
|
| Growth | BLFS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.9% | 7.8% | 73% |
|
| Net Income (5yr) | (33.9%) | (11.2%) | 12% |
|
| EPS (5yr) | (9.9%) | 2.5% | 21 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.4%) | (15.0%) | 35% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.070 | $0.250 | $0.330 | |
| Month Ago EPS | $0.070 | $0.250 | $0.330 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.070 | $0.250 | $0.290 | |
| Year/Year Chg | (92.3%) | (198.4%) | (434.6%) | |
| Financials | BLFS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $107 | $810 | 27% |
|
| Net Income (TTM) (Mil) | $58 | ($31) | 56% |
|
| EPS (TTM) | $1.199 | ($0.300) | 63% |
|
| Operating Cash Flow (TTM) (Mil) | $17 | $56 | 40% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $13 | $264 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,711 | $3,795 | 47% |
|
| Valuation | BLFS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.18 | 3.86 | 74% |
|
| P/E | 36.4 | 38.5 | 76% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.8 | na |
|
| Ratios | BLFS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.6% | 47.6% | 76% |
|
| Net Margin | 54.3% | (2.6%) | 97% |
|
| ROA | 13.9% | (4.0%) | 92% |
|
| ROE | 15.1% | (7.7%) | 71% |
|
| Liabilities to Assets | 6.1% | 41.1% | 3% |
|
| F-Score | 5 | 5 | na |
|
BioLife Solutions, Inc. did not pass any screens on 9/2/2026.
